Skip to content

    CRISPR Therapeutics AG (CRSP) financials

    Overview

    Price

    Market Cap

    Sector

    Rank

    Performance+7.8% 1Y

    Financials

    Income Statement

    Financial Trajectories

    11
    Quarterly
    MetricQ3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Trend
    EarningsRevenue
    $602.0K
    $35.69M
    $865.0K
    $892.0K
    $889.0K
    +47.7%
    $864.0K
    -97.6%
    $1.46M
    +68.6%
    $10.18M
    +1041.4%
    Strengthening
    Operating Profit
    -$110.13M
    -$64.59M
    -$148.42M
    -$229.32M
    -$132.06M
    -19.9%
    -$154.76M
    -139.6%
    -$130.25M
    +12.2%
    -$117.27M
    +48.9%
    Weakening
    Net Profit
    -$85.94M
    -$37.31M
    -$136.00M
    -$208.55M
    -$106.44M
    -23.9%
    -$130.61M
    -250.1%
    -$122.93M
    +9.6%
    -$91.15M
    +56.3%
    Weakening
    EPS
    $-1.01
    $-1.58
    $-2.40
    $-1.17
    -15.8%
    $-1.28
    +19.0%
    $-0.94
    +60.8%
    Strengthening
    Other Income
    $25.06M
    $27.98M
    $13.54M
    $22.07M
    $26.24M
    +4.7%
    $24.77M
    -11.5%
    $8.16M
    -39.8%
    $27.07M
    +22.7%
    Weakening
    Interest
    Depreciation
    Profit before Tax
    -$85.07M
    -$36.61M
    -$134.89M
    -$207.26M
    -$105.82M
    -24.4%
    -$130.00M
    -255.1%
    -$122.09M
    +9.5%
    -$90.19M
    +56.5%
    Weakening
    MarginsOPM
    -18294.0%
    -181.0%
    -17158.8%
    -25709.0%
    -14854.8%
    +18.8%
    -17912.5%
    -9798.0%
    -8933.3%
    +47.9%
    -1151.8%
    +95.5%
    Weakening
    Tax
    -1.0%
    -1.9%
    -0.8%
    -0.6%
    -0.6%
    +43.7%
    -0.5%
    +75.4%
    -0.7%
    +15.9%
    -1.1%
    -71.0%
    Strengthening
    ReturnsROIC
    2.0%
    0.9%
    3.2%
    4.9%
    2.5%
    +23.9%
    3.1%
    +250.1%
    2.9%
    -9.6%
    2.2%
    -56.3%
    Strengthening

    Balance Sheet

    Balance Sheet

    USD · Annual
    Line itemFY18FY19FY20FY21FY22FY23FY24FY25TTM
    AssetsCash & Equivalents$456.65M$943.77M$1.17B$923.03M$211.88M$389.48M$298.26M$347.56M$291.34M
    Short-Term Investments$0$521.71M$1.46B$1.60B$1.30B$1.61B$1.63B$2.07B
    Total Current Assets$466.39M$987.55M$1.72B$2.42B$1.85B$1.91B$1.94B$1.99B$2.37B
    Net PP&E$18.50M$72.83M$93.03M$312.04M$320.56M$305.94M$277.55M$247.57M$233.66M
    Goodwill
    Intangibles$289.0K$235.0K$180.0K$125.0K$71.0K$16.0K$0
    Total Assets$489.02M$1.07B$1.83B$2.75B$2.24B$2.23B$2.24B$2.27B$2.65B
    LiabilitiesTotal Current Liabilities$27.75M$57.11M$94.26M$119.88M$121.11M$108.79M$87.78M$149.12M$132.90M
    Short-Term Debt
    Long-Term Debt$0$586.20M
    Long-Term Leases$44.05M$50.07M$212.87M$228.18M$223.01M$206.41M$188.17M$178.90M
    Total Liabilities$96.82M$127.33M$163.73M$352.42M$367.58M$346.77M$309.95M$343.43M$904.22M
    EquityCommon Stock & APIC$1.58M$1.85M$2.28M$2.39M$2.44M$2.50M$2.70M$3.09M$3.13M
    Retained Earnings-$291.57M-$224.71M-$573.58M-$195.91M-$846.09M-$999.70M-$1.37B-$1.95B-$2.16B
    Total Equity$392.19M$939.42M$1.66B$2.40B$1.88B$1.88B$1.93B$1.92B$1.75B
    HighlightsNet Cash / (Debt)

    Cash Flow

    Cash Flow

    USD · Annual
    Line itemFY18FY19FY20FY21FY22FY23FY24FY25TTM
    ActivitiesCash from Operating-$96.24M$56.68M-$238.37M$538.97M-$495.74M-$260.38M-$142.77M-$345.01M-$369.58M
    Cash from Investing-$2.77M$1.32M-$541.17M-$1.04B-$258.65M$374.65M-$280.48M-$31.80M-$548.43M
    Cash from Financing$315.93M$430.98M$1.02B$250.94M$38.59M$62.66M$331.98M$426.03M$1.01B
    SummaryCapital Expenditure-$2.77M-$6.68M-$18.36M-$81.70M-$37.19M-$9.47M-$1.90M-$914.0K-$1.74M
    Free Cash Flow-$99.01M$49.99M-$256.72M$457.27M-$532.93M-$269.85M-$144.68M-$345.93M-$371.32M
    FCF Margin-3169.4%17.3%-35705.7%50.0%-44484.9%-72.7%-387.7%-9855.5%-2772.7%

    Ratios